Abstract:The TEMPI syndrome is a rare multi-systemic disease, characterize by telangiectasias, elevated erythropoietin and erythrocytosis, monoclonal gammopathy, perinephric fluid collections, and intrapulmonary shunting (Sykes et al, N Engl J Med 2011). Plasma cell is supposed to play a pathogenic role in the syndrome (Sykes et al, Blood 2020), but the underlying molecular mechanism remains poorly understood. Here, we introduced a novel IRF4-BLOC1S5 fusion gene in the TEMPI syndrome, highly expressed in the monoclonal plasma cell population. We presented one case of the TEMPI syndrome with typical clinical symptoms. The patient received bortezomib and dexamethasone treatment. After 4 cycles of treatment, the patient achieved a satisfied response with a negative MRD. The symptoms were relieved, with the disappearance of the cyanosis, telangiectasias, perinephric-fluid collection, and serum M protein, amelioration of intrapulmonary shunting, normalization of erythrocyte count and erythropoietin level. To explore the possible mechanism of the TEMPI syndrome, we performed whole genome sequencing and transcriptome analysis to identify genomic and transcriptomic abnormalities of our patient. WGS of paired tumor (CD138 + plasma cells) and normal samples revealed a somatic inversion on chromosome 6. Bulk RNA-Seq showed that this inversion caused an out-of-frame fusion transcript IRF4-BLOC1S5, which generated a short N-terminal-truncated IRF4 protein. Western blotting confirmed that the corresponding truncated-IRF4 protein was expressed in the CD138 + plasma cells, but not CD138 - cells of this patient and normal donors, as well as MM samples. We performed single cell RNA-sequencing to identify distinct clusters of this patient and found a strong expansion (11.2-fold) of plasma population companied with high expression of truncated-IRF4 in our patient in the case and this unique expanded plasma cluster expressed one specific immunoglobulin clonotype sharing the same CDR3 sequence. Functional analysis illustrated that differentially expressed genes in plasma cells between this patient and healthy controls were enriched in the KEGG pathways such as ribosome and protein processing in endoplasmic reticulum. Besides, the expression of IRF4-BLOC1S5 was only detected at diagnosis and significantly decreased after the BD treatment and in the clinical follow-up (up to 18 months). IRF4-BLOC1S5 may serve as a molecular marker to surveille the disease progression of this patient. In conclusion, IRF4-BLOC1S5 is the first fusion gene reported in the TEMPI syndrome. IRF4-BLOC1S5 was highly proposed to play an important role in the pathophysiology of the TEMPI syndrome based on the high correlation between IRF4-BLOC1S5 expression level and symptoms of the syndrome. More molecular events responsible for the TEMPI syndrome still await to be identified, albeit a ultrarare occurrence of this disease. An intensive international collaboration is strongly proposed to completely elucidate its molecular mechanisms.

Case Report: TEMPI syndrome: Report of three cases and treatment follow-up

TEMPI Syndrome: Update on Clinical Features, Management, and Pathogenesis

TEMPI syndrome: difficult to diagnose, "easy" to treat?

Whole-genome sequencing suggests a role of MIF in the pathophysiology of TEMPI syndrome

IRF4-BLOC1S5, the First Genomic Fusion Gene Identified in the TEMPI Syndrome

First use of 18F-FDG PET in TEMPI syndrome: can it be used for treatment assessment? A case report

Diagnosis and management of acquired thrombotic thrombocytopenic purpura in southeast China: a single center experience of 60 cases

Kaposiform Hemangioendothelioma Presented with Raynaud Phenomenon: a Case Report

Surgical management of monomorphic epitheliotropic intestinal T-cell lymphoma followed by chemotherapy and stem-cell transplant: A case report and review of the literature

A rare case of TEMPI syndrome (telangiectasias, erythrocytosis, monoclonal gammopathy and ascites) associated with IgM monoclonal gammopathy

A Case Report of POEMS Syndrome with Renal Involvement As Immunotactoid Glomerulopathy

Case Report: Apatinib Plus Selexipag As a Novel Therapy for Pulmonary Tumor Thrombotic Microangiopathy Accompanied by Pulmonary Hypertension Associated with Gastric Carcinoma.

Case Report: ITP Treatment After CAR-T Cell Therapy in Patients With Multiple Myeloma

Tumor induced osteomalacia complicated with deep vein thrombosis and pulmonary embolism: report of two cases and literature review

POEMS Syndrome: A Report of 14 Cases and Review of the Literature

Primary erythromelalgia mainly manifested by hypertensive crisis: A case report and literature review

Case report: POEMS syndrome with portal hypertension

Polyneuropathy, organomegaly, endocrinopathy, M-protein, skin changes syndrome with dilated cardiomyopathy: A case report

A case of POEMS syndrome comprising of a complicated diagnostic procedure: Case report

Clinical Characteristics and the Long-Term Outcome of Patients with Atypical POEMS Syndrome Variant with Undetectable Monoclonal Gammopathy.

Clinical Analysis of 14 Cases of POEMS Syndrome